@ 206
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reading every post here today and the board has 11 boardmarks - gonna have some questions for some of you :)
RGIN - list of presenters at onemedforum a few days ago -
link: http://www.onemedplace.com/forum/livewebcast
Companies
Tuesday
8:30:00 Bacterin International
8:45:00 IRIDEX Corporation
9:00:00 Ophthalmic Imaging Systems
9:15:00 EpiCept Corporation
9:30:00 Synergetics USA
9:45:00 Cytori Therapeutics
10:00:00 ADVENTRX Pharmaceuticals
10:15:00 IntelGenx Corp.
10:30:00 Advaxis
10:45:00 Neoprobe
11:00:00 Spherix Incorporated
11:15:00 diaDexus
11:30:00 Cyclacel Pharmaceuticals
11:45:00 Vyteris, Inc.
12:00:00 Novadaq Technologies Inc.
12:15:00
1:45:00 Adeona Pharmaceuticals
2:00:00 Cambridge Heart
2:15:00 CytoSorbents Corporation
2:30:00 DATATRAK International
2:45:00 BioCurex
3:00:00 Cardium Therapeutics
3:30:00 Tianyin
3:45:00 STENTYS
4:00:00 Regenicin
4:15:00 Echo Therapeutics
4:30:00 Alverix
4:40:00 Medomics
4:50:00 Healthlink
RGIN - link to San Francisco attendance @ onemedforum;
http://www.onemedplace.com/database/list/cid/14391
RGIN December - Regenicin CEO to Present at OneMedForum Business Development and Finance Conference
Date : 12/22/2010 @ 8:30AM
Source : PR Newswire
Regenicin CEO to Present at OneMedForum Business Development and Finance Conference
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will participate in the 4th Annual OneMedForum on January 11-13, 2011 in San Francisco. Randall McCoy, CEO of Regenicin, will present the company's core concept and business model for bringing new regenerative medicine products to market.
The Forum will bring together some of the most promising emerging medtech and life science companies with strategic and financial investors focused on companies and new technologies. Focused panel sessions will also help CEOs connect with financial and strategic investors involved in specific sectors and will include networking and breakout sessions.
The conference is considered the healthcare finance community's largest gathering of the year. More information about the conference can be found at http://www.onemedplace.com/forum/.
RGIN November - Regenicin, Inc. Receives Central Contractor Registration (CCR)
Date : 11/30/2010 @ 8:00AM
Source : PR Newswire
Stock : Regenicin, Inc. Common Stock (RGIN)
Regenicin, Inc. Receives Central Contractor Registration (CCR)
Regenicin, Inc. (OTCBB:RGIN)
Historical Stock Chart
2 Months : November 2010 to January 2011
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, recently received its Central Contractor Registration (CCR) from the U.S. Government. The registration qualifies Regenicin to receive funding from the Federal Government through contracts, grants, cooperative agreements and other forms of federal assistance.
The Central Contractor Registration is the primary registrant database for the U.S. Federal Government. A CCR registration is required prior to being awarded a contract with any federal government agency. The CCR also serves as a search engine for contracting officers and a link to current procurement opportunities.
"Obtaining our CCR makes us eligible to apply for Federal Grants that could support Regenicin in the development and commercialization of current and future therapeutic candidates," says Chris Hadsall, COO for Regenicin. "This is an important milestone since the government has already provided, and is expected to continue to provide millions of dollars in grants to advancements in regenerative medicine."
RGIN November - Department of Defense Provides Funding to Lonza to Move Therapeutic Candidate PermaDerm™ into the First Clinical Trials for Adul
Date : 11/22/2010 @ 8:00AM
Source : PR Newswire
Department of Defense Provides Funding to Lonza to Move Therapeutic Candidate PermaDerm™ into the First Clinical Trials for Adul
The U.S. Department of Defense recently awarded more than $18 million in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm™ for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.
Regenicin, Inc. (OTC Bulletin Board: RGIN), has an agreement with Lonza pursuant to which Regenicin has been charged to obtain FDA approval for the commercial sale of PermaDerm. The funding will assist Regenicin and Lonza in advancing the clinical trials to be conducted in connection with the FDA approval process. Regenicin was a presenter at the conference at which the funding was awarded.
PermaDerm™, an engineered skin substitute grown from a patient's own skin cells, has already been used to treat more than 150 pediatric, catastrophic burn victims through an Investigation Device Exemption issued by U.S. Food and Drug Administration (FDA).
This is PermaDerm's first clinical trial to be conducted on adults, a major milestone for achieving pre-market approval by the FDA.
The initial trial will contain 10 patients, both male and female, between the ages of 18 and 40, who suffer third-degree burns. These trials and future trials will take place at the United States Army Institute of Surgical Research at Fort Sam Houston and at a second site to be determined.
RGIN November - Regenicin CEO to Speak at Proactive Investor Conference in New York, NY November 18th, 2010
Date : 11/18/2010 @ 12:26PM
Source : PR Newswire
Stock : Regenicin, Inc. Common Stock (RGIN)
Quote : 0.84 0.15 (21.74%) @ 4:01PM
Regenicin CEO to Speak at Proactive Investor Conference in New York, NY November 18th, 2010
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will be represented by company CEO, Randall McCoy at the Proactive Investor Conference today at the Intercontinental New York Barclay Hotel.
Mr. McCoy will present Regenicin's core concept and business model for bringing regenerative medicine products to market. Regenicin will be among five public biotechnology and medical technology companies that will be presenting to institutional and private investors.
RGIN November - start paying attention to comments of Dr. Craig Eagle who is with industry giant Pfizer, and industry leader Lonza's role.
Regenicin Participates in Regenerative Medicine Conference
Date : 11/17/2010 @ 8:30AM
Source : PR Newswire
Stock : Regenicin, Inc. Common Stock (RGIN)
Regenicin Participates in Regenerative Medicine Conference
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, recently participated in a conference celebrating the latest advancements in regenerative medicine. More than one hundred people and organizations attended the event in Walkersville, MD to reinforce their commitment to developing and delivering new cellular treatments to the patients who need them.
The conference was hosted on November 9th, by Lonza Walkersville, Inc. a subsidiary of Lonza AG, a Swiss based life science company and one of the world's leading cell therapy manufacturers. Presenters and participants emphasized the importance of nurturing public-private partnerships to support the development and delivery of new therapies for the treatment of U.S. troops and civilians.
In attendance was The U.S. Department of Defense Office of Technology Transition, the Armed Forces Institute of Regenerative Medicine, as well as members of Congress, U.S. Armed Forces personnel, scientists, firefighters, and surgeons on the frontlines of treating burns and wounds in the U.S.
Dr. Craig Eagle, who serves on Regenicin's Board of Directors, presented at the conference. "I was very moved by the solidarity and commitment of all parties, to seek out, develop and deliver new treatments for disease and catastrophic injuries," says Eagle.
RGIN November - Regenicin CEO to Speak at LifeTech Investor Conference in Miami, Florida November 12th, 2010
Date : 11/12/2010 @ 8:52AM
Source : PR Newswire
Stock : Regenicin, Inc. Common Stock (RGIN)
Regenicin CEO to Speak at LifeTech Investor Conference in Miami, Florida November 12th, 2010
Regenicin, Inc. (OTCBB:RGIN)
Historical Stock Chart
3 Months : October 2010 to January 2011
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, will be represented by company CEO, Randall McCoy at the 1st Annual LifeTech Investor Conference at the JW Marriott Marquis today in Miami.
Mr. McCoy will present Regenicin's core concept and business model for bringing regenerative medicine products to market. Regenicin will be among twenty four public biotechnology and medical technology companies that will be presenting to institutional and private investors.
In addition to Regenicin, the conference will feature the University of Miami Miller School of Medicine Technology Showcase as well as panels of experts from their renowned centers such as the Sylvester Cancer Center, the Bascom Palmer Eye Institute and the Stem Cell Institute. For more information and free registration, visit http://www.LifeTechCapital.com/conference.
RGIN November - Regenicin Announces Closing of Private Placement Transaction
Date : 11/11/2010 @ 3:31PM
Source : PR Newswire
Stock : Regenicin, Inc. Common Stock (RGIN)
Regenicin Announces Closing of Private Placement Transaction
Regenicin, Inc. (OTCBB:RGIN)
Historical Stock Chart
3 Months : October 2010 to January 2011
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced the closing of a private placement. Regencin secured proceeds of $467,550.25. In addition the company converted $500,000 of debt into equity.
The proceeds, net of placement agent fees and expenses, will be used to continue to develop its innovative regenerative medicine platform.
RGIN timeline - recap of events - this is a hidden gem imo and dollars coming -
Let's start here when the stock was 2.00 per share
http://www.prnewswire.com/news-releases/regenicin-completes-acquisition-of-worldwide-exclusive-know-how-technology-license-from-lonza-walkersville-100968639.html
Lonza to Provide Exclusive Manufacturing Services to Regenicin for new Proprietary Skin Production Technology
NEW YORK, Aug. 18 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement"). Lonza Walkersville is a subsidiary of Lonza Group Ltd. (SIX: LONN), one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries and the largest cell therapy manufacturer in the world.
The Lonza Agreement provides Regenicin with the worldwide marketing rights to a proprietary tissue-engineered skin substitute technology intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. Regenicin's management team intends to use its expertise, with the assistance of Lonza Walkersville, to further enhance its capabilities and seek approval by the U.S. Food and Drug Administration for commercial sale. Regenicin plans to seek marketing approval for this revolutionary product throughout the world under the brand name PermaDerm™.
RGIN - tweets from Mike Havrilla and BioRunUp.com;
@mikehavrilla
Mike Havrilla
Regenicin - Several FDA and Clinical Trial Catalysts Pending http://goo.gl/fb/ljRMh
6 hours ago
BioRunUp BioRunUp
BioRunUp Article:: Regenicin - Several FDA and Clinical Trial Catalysts Pending http://bit.ly/dWabwq
6 hours ago
http://twitter.com/mikehavrilla
http://twitter.com/BioRunUp
RGIN - tweets from Mike Havrilla and BioRunUp.com;
@mikehavrilla
Mike Havrilla
Regenicin - Several FDA and Clinical Trial Catalysts Pending http://goo.gl/fb/ljRMh
6 hours ago
BioRunUp BioRunUp
BioRunUp Article:: Regenicin - Several FDA and Clinical Trial Catalysts Pending http://bit.ly/dWabwq
6 hours ago
http://twitter.com/mikehavrilla
http://twitter.com/BioRunUp
Company quiet for some time, my bet is they have been working and will see news soon. Last time we accumulated this below .02 it ran huge to .15 with huge bank for many :)
RGIN chart - link back - huge volume and money flow coming into this today
CHMD looking very good today :)
RGIN .87 last +23% - huge volume coming in today
RGIN running .89 last
RGIN .79 last now level 2 lighting up :)
RGIN .75 last - waking up :)
RGIN .745 starting to wake up in the last few minutes
Always - when the crowd shows it will go for sure - been buying this for weeks and so has my mom - this is a good time to accumulate before the street shows up on it - it will happen imo - the question is when - this management, BOD and the events within the company will not go unnoticed forever.
Real easy double on this one imo - with patience much much more.
Rain - not sure about solution - they should get that fixed as there have been many F stocks running and many of them are mineral plays that trade under the F. ( i have a couple currently)
Maybe Etrade has a solution, maybe be worth checking into as F's have been much more active than previous years.
Currently 11:55 am ET DIAAF;
NOBL - AUTO best bid .072 with total 5 mm's bidding .07 or higher
NOBL appeared this morning
Offers;
NITE .075
VERT
AUTO .076
HDSN
NOBL .095
CSTI .10
DOMS
SJLS
STXG
This one hidden - THUS FAR
Here is a link to the press on the conference held a few days ago;
http://www.regenicin.com/press-releases.html?__rst=MTJ8YmZ8NmR8NTd8ZGN8OTB8ZDd8NDl8NDB8NWF8M2Z8NTB8NTR8ZmF8ZDR8YTF8ZGZ8YTZ8YjN8ZGR8NDd8YjV8M2V8MTN8OWJ8OGN8YTN8Njl8NjF8ZTF8ZTZ8N2V8
When people start looking into it and find Dr. Craig Eagle of Pfizer is with RGIN it will start getting much attention.
Dr. Craig Eagle
Pfizer Oncology
Dr. Craig Eagle joined Pfizer Australia in 2001 as part of the medical group. In Australia, his role involved leading and participating in scientific research, regulatory and pricing & re-imbursement negotiations for compounds in therapeutic areas including oncology, anti-infectives, respiratory, arthritis and pain management. In 2003, Pfizer relocated Dr. Eagle to the United States where he was appointed as the worldwide lead for development of Celecoxib in oncology to oversee the global research program. Since that time he has had increasing responsibility for overseeing the global research plans and teams for Irinotecan and Dalteparin. In 2007, he became head of Medical Affairs and Outcomes Research for Pfizer, including the US oncology business. Dr. Eagle has led, or been directly involved with, teams that resulted in eight new products or indications. As part of his current role at Pfizer, he has led the integration of the Pfizer/Wyeth oncology businesses and portfolio.
And of course Dr. Rubinfeld, one of the initial founders of Amgen;
Dr. Joseph Rubinfeld, Ph.D
Director at CytRX; Initial Co-Founder of Amgen, Inc.
Dr. Joseph Rubinfeld co-founded SuperGen, Inc. in 1991 and has served as its Chief Executive Officer and President, Chief Scientific Officer and as a director. He has been a director of CytRX since July 2002. Dr. Rubinfeld is also a founder of JJ Pharma. Dr. Rubinfeld was one of the four initial founders of Amgen, Inc. in 1980 and served as a Vice President and its Chief of Operations until 1983. From 1987 until 1990, Dr. Rubinfeld was a Senior Director at Cetus Corporation and from 1968 to 1980, Dr. Rubinfeld was employed at Bristol-Myers Company. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and an M.A. and Ph.D in chemistry from Columbia University.
http://www.regenicin.com/board-of-directors.html
CHMD got starter yest and today :) thanks for all your great work on this Rain
i am at a diff computer today, please resend me your email :)
m